Search
Protein SLC31A2
go.drugbank.com/bio_entities/BE0003662TransporterHumansDoes not function as a copper(1+) importer in vivo (By similarity). However, in vitro functions as a low-affinity copper(1+) importer (PubMed:17617060, PubMed:17944601). … export and modulates the copper and cisplatin accumulation via SLC31A1 (By similarity)
Synonyms: Copper transporter 2Function: copper ion transmembrane transporter activityPraziquantel
go.drugbank.com/drugs/DB01058ApprovedInvestigationalVet approved[A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030
Carprofen
go.drugbank.com/drugs/DB00821ApprovedVet approvedWithdrawnCarprofen was previously used in human medicine for over 10 years (1985-1995). … It is no longer marketed for human usage, after being withdrawn on commercial grounds.
Nesiritide
go.drugbank.com/drugs/DB04899ApprovedInvestigationalWithdrawnNesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is a 32 amino acid recombinant human B-type natriuretic p...
Categories: Vasodilators Used in Cardiac DiseasesFlosequinan
go.drugbank.com/drugs/DB13228ApprovedWithdrawnFlosequinan was approved in the USA and the UK for a year prior to being withdrawn from the market due to increased mortality in chronic heart failure patients, found in drug trials.[A174979,L43942]
Categories: Vasodilators Used in Cardiac DiseasesStannous chloride
go.drugbank.com/drugs/DB11056ApprovedStannous chloride is used as a source of tin in radiopharmaceutical kits. … These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue [FDA Label].
Ticagrelor
go.drugbank.com/drugs/DB08816ApprovedInvestigational[A2903] It is marketed by Astra Zeneca as Brilinta in the US[L14201] and Brilique or Possia in the EU,[L14207]. Ticagrelor was granted EMA approval on 3 December 2010. … Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism.
Tolcapone
go.drugbank.com/drugs/DB00323ApprovedInvestigationalWithdrawnIt is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound.
International brands: Sen De NingOxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.
International brands: Staficilin-NGlofitamab
go.drugbank.com/drugs/DB16371ApprovedInvestigational[L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies - … , after two or more lines of systemic therapy under accelerated approval based on response rate and durability of response.